Spleen-Kidney Supplementing Formula Alleviates Renal Fibrosis in Diabetic Rats via TGF-β1-miR-21-PTEN Signaling Pathway

Figure 5

Influence of SKSF on TGF-β1 expression. (A) Normal group, (B) model group, (C) metformin group, (D) Spleen-Kidney Supplementing Formula group at a high dose, (E) Spleen-Kidney Supplementing Formula group at a medium dose, (F) Spleen-Kidney Supplementing Formula group at a low dose. Data were expressed as mean ± SD, n =10 rats per group. ^∗P < 0.05, ^∗∗P <0.01 compared with model group.

(a)

(b)